Jupiter Neurosciences Inc
JUNS1.466USD
+0.106+7.80%
Market hours （ET）Quotes delayed by 15 min
48.53MMarket Cap
LossP/E TTM
More Details of Jupiter Neurosciences Inc Company
Jupiter Neurosciences, Inc. is a clinical-stage research and development pharmaceutical company. The Company has developed a resveratrol platform product targeting treatment of neuro-inflammation. Its product, JOTROL, has many potential indications of use for rare diseases, which of it primarily is targeting Mucopolysaccharidoses Type 1, Friedreich's Ataxia, and Mitochondrial Encephalopathy, Lactic Acidosis, and Stroke-like episodes (MELAS). In the larger disease areas, the Company is primarily targeting Parkinson's Disease and Mild Cognitive Impairment/early Alzheimer’s disease. The Company has designated the different indications with project numbers, JNS101 - JNS115. JOTROL is a micellar non-aqueous solution of resveratrol delivered in a soft gel capsule. Each capsule includes 100 milligrams (mg) of resveratrol. It has a worldwide license, from Aquanova AG, the patent holder of micellar technologies, to develop, manufacture, distribute and sell JOTROL.
Company Info
Ticker SymbolJUNS
Company nameJupiter Neurosciences Inc
IPO dateDec 03, 2024
CEOMr. Christer Rosen
Number of employees4
Security typeOrdinary Share
Fiscal year-endDec 03
Address1001 North US HWY 1, Suite 504
CityPALM BEACH GARDENS
Stock exchangeNASDAQ Capital Market Consolidated
CountryUnited States of America
Postal code33477
Phone15614066154
Websitehttps://jupiterneurosciences.com/
Ticker SymbolJUNS
IPO dateDec 03, 2024
CEOMr. Christer Rosen
Company Executives
Name
Name/Position
Position
Shareholding
Change
Mr. Christer Rosen
Mr. Christer Rosen
Chairman of the Board, Chief Executive Officer, Co-Founder
Chairman of the Board, Chief Executive Officer, Co-Founder
11.55M
+0.03%
Mr. Alexander Gustaf Erik Rosen
Mr. Alexander Gustaf Erik Rosen
Co-Founder, Chief Administrative Officer
Co-Founder, Chief Administrative Officer
452.86K
--
Ms. Alison D Silva
Ms. Alison D Silva
President, Chief Business Officer, Director
President, Chief Business Officer, Director
112.78K
+0.67%
Ms. Allison W. Brady
Ms. Allison W. Brady
Director
Director
21.75K
--
Mr. Holger Weis, CPA
Mr. Holger Weis, CPA
Director
Director
10.78K
--
Mr. Nicholas H. Hemmerly
Mr. Nicholas H. Hemmerly
Director
Director
--
--
Mr. Saleem Elmasri, CPA
Mr. Saleem Elmasri, CPA
Chief Financial Officer
Chief Financial Officer
--
--
Ms. Julie Kampf
Ms. Julie Kampf
Director
Director
--
--
Dr. Marshall A Hayward, Ph.D.
Dr. Marshall A Hayward, Ph.D.
Co-Founder, Chief Scientific Officer, Director
Co-Founder, Chief Scientific Officer, Director
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Christer Rosen
Mr. Christer Rosen
Chairman of the Board, Chief Executive Officer, Co-Founder
Chairman of the Board, Chief Executive Officer, Co-Founder
11.55M
+0.03%
Mr. Alexander Gustaf Erik Rosen
Mr. Alexander Gustaf Erik Rosen
Co-Founder, Chief Administrative Officer
Co-Founder, Chief Administrative Officer
452.86K
--
Ms. Alison D Silva
Ms. Alison D Silva
President, Chief Business Officer, Director
President, Chief Business Officer, Director
112.78K
+0.67%
Ms. Allison W. Brady
Ms. Allison W. Brady
Director
Director
21.75K
--
Mr. Holger Weis, CPA
Mr. Holger Weis, CPA
Director
Director
10.78K
--
Mr. Nicholas H. Hemmerly
Mr. Nicholas H. Hemmerly
Director
Director
--
--
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Wed, Jul 9
Updated: Wed, Jul 9
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Rosen (Christer)
34.90%
Wahlestedt (Claes M.D., Ph.D.)
8.47%
Hayward (Marshall A Ph.D.)
7.19%
Brothers (Shaun P.)
5.13%
Rosen (Alexander Gustaf Erik)
1.37%
Other
42.94%
Shareholders
Shareholders
Proportion
Rosen (Christer)
34.90%
Wahlestedt (Claes M.D., Ph.D.)
8.47%
Hayward (Marshall A Ph.D.)
7.19%
Brothers (Shaun P.)
5.13%
Rosen (Alexander Gustaf Erik)
1.37%
Other
42.94%
Shareholder Types
Shareholders
Proportion
Individual Investor
57.70%
Investment Advisor
0.49%
Research Firm
0.34%
Hedge Fund
0.31%
Investment Advisor/Hedge Fund
0.03%
Other
41.13%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
18
19.49M
58.89%
+1.54M
2025Q1
16
18.33M
55.39%
+383.02K
2024Q4
9
17.92M
54.13%
+14.81M
2024Q3
6
5.31M
79.52%
--
2024Q2
10
5.31M
79.52%
-11.63K
2024Q1
10
5.31M
79.52%
-11.63K
2023Q4
10
5.31M
79.52%
-11.63K
2023Q3
10
5.31M
79.52%
-11.63K
2023Q2
10
5.31M
79.52%
-11.63K
2023Q1
11
5.31M
79.57%
-15.77K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Rosen (Christer)
11.55M
34.89%
+981.28K
+9.29%
Jun 30, 2025
Wahlestedt (Claes M.D., Ph.D.)
2.80M
8.47%
--
--
Mar 12, 2025
Hayward (Marshall A Ph.D.)
2.38M
7.19%
--
--
Mar 12, 2025
Brothers (Shaun P.)
1.70M
5.13%
--
--
Mar 12, 2025
Rosen (Alexander Gustaf Erik)
452.86K
1.37%
--
--
Mar 12, 2025
UBS Financial Services, Inc.
135.64K
0.41%
+135.62K
+542460.00%
Mar 31, 2025
Silva (Alison D)
112.03K
0.34%
+112.03K
--
Jun 30, 2025
Citi Investment Research (US)
111.98K
0.34%
+107.49K
+2393.92%
Mar 31, 2025
Two Sigma Investments, LP
90.19K
0.27%
+90.19K
--
Mar 31, 2025
Elmasri (Saleem C)
66.29K
0.2%
+66.29K
--
Jun 02, 2025
View more
Related ETFs
Updated: Sat, Aug 2
Updated: Sat, Aug 2
Name
Proportion
iShares Micro-Cap ETF
0%
iShares Micro-Cap ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
